Enanta Pharmaceuticals, Inc. (ENTA) — Financial statements
Income statement, balance sheet, and cash flow for Enanta Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 65↓3.4% | 68↓14.6% | 79↓8.1% | 86↓11.2% | 97 | |
| Cost of Revenue | 5 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 61↓10.2% | 68↓14.6% | 79↓8.1% | 86↓11.2% | 97 | |
| Operating Expenses | ||||||
| R&D Expenses | 107↓18.8% | 131↓19.6% | 164↓0.6% | 165↓5.5% | 174 | |
| General & Administrative Expenses | 44↓24.1% | 58↑9.4% | 53↑16.3% | 45↑39.8% | 33 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 44↓24.1% | 58↑9.4% | 53↑16.3% | 45↑39.8% | 33 | |
| Other Expenses | -5 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 146↓22.8% | 189↓12.5% | 216↑3.1% | 210↑1.6% | 207 | |
| Total Costs & Expenses | 151↓20.4% | 189↓12.5% | 216↑3.1% | 210↑1.6% | 207 | |
| Operating Results | ||||||
| Operating Income | -85↑29.9% | -122↑11.3% | -137↓10.8% | -124↓13.0% | -110 | |
| Depreciation & Amortization | 5↑117.9% | 2↓1.5% | 2↓20.2% | 3↓10.8% | 3 | |
| EBITDA | -71↑32.3% | -105↑15.4% | -123↓3.6% | -119↓14.4% | -104 | |
| EBIT | -76↑29.0% | -107↑15.1% | -126↓3.0% | -122↓13.6% | -108 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↓53.0% | 4↓38.3% | 6↑294.9% | 2↓22.2% | 2 | |
| Interest Income | 9↓35.8% | 15↑30.0% | 11↑622.2% | 2↓22.2% | 2 | |
| Interest Expense | 8↓29.8% | 11↑112.5% | 5 | 0.00 | 0.00 | |
| Non-Operating Income | -9↑36.1% | -15↓30.7% | -11↓586.0% | -2↑17.0% | -2 | |
| Other Income / Expenses | 2↓53.9% | 4↓37.2% | 6↑275.1% | 2↓17.0% | 2 | |
| Income Before Tax | -84↑29.1% | -118↑10.1% | -131↓7.2% | -122↓13.6% | -108 | |
| Income Tax Expense | -2↑4.8% | -2↓161.8% | 3↑751.5% | -0.43↑98.5% | -29 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -82↑29.4% | -116↑13.3% | -134↓9.9% | -122↓54.1% | -79 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -82↑29.4% | -116↑13.3% | -134↓9.9% | -122↓54.1% | -79 | |
| Bottom-Line Net Income | -82↑29.4% | -116↑13.3% | -134↓9.9% | -122↓54.1% | -79 | |
| EPS (Basic) | -3.84↑29.9% | -5.48↑14.1% | -6.38↓8.0% | -5.91↓50.8% | -3.92 | |
| EPS (Diluted) | -3.84↑29.9% | -5.48↑14.1% | -6.38↓8.0% | -5.91↓50.8% | -3.92 | |
| Weighted Average Shares | 21↑0.8% | 21↑0.9% | 21↑1.8% | 21↑2.1% | 20 | |
| Weighted Average Diluted Shares | 21↑0.8% | 21↑0.9% | 21↑1.8% | 21↑2.1% | 20 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.